Form 4: Clorox Executive Acquires 3,364 Shares via RSU Grant

Clorox EVP Stacey Grier acquired 3,364 shares of common stock through a Restricted Stock Unit grant, increasing her beneficial ownership to 23,190 shares.

Summary

• Stacey Grier, EVP Executive Chief of Staff at Clorox Co, acquired 3,364 shares of common stock.
• The acquisition was made through a Restricted Stock Unit (RSU) grant at a deemed price of $124.85 per share.
• Following this transaction, Ms. Grier beneficially owns 23,190 shares of Clorox common stock.
• The RSUs will vest in four equal installments on October 5, 2026, 2027, 2028, and 2029.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive through an RSU grant is generally viewed positively as it increases management's alignment with shareholder interests and serves as a long-term incentive. It's a routine compensation event, not indicative of extraordinary news, hence a moderate positive score.

Positives

• Increased alignment between executive management and shareholder interests through equity ownership.
• The grant of Restricted Stock Units serves as a retention and incentive mechanism for a key executive.

Negatives

• No negative aspects are indicated in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The future outlook indicates a structured vesting schedule for the Restricted Stock Units, with installments occurring annually from October 2026 through October 2029, aligning executive incentives with long-term company performance.

Industry Context

This RSU grant is a standard practice in executive compensation across various industries, designed to incentivize long-term performance and retain key talent by linking executive wealth to shareholder value creation. It reflects a common approach to aligning management interests with those of the company's investors.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice among publicly traded companies, including peers in the consumer staples sector such as Procter & Gamble (PG) and Kimberly-Clark (KMB).
• The vesting schedule, typically over several years, is consistent with industry norms aimed at fostering long-term commitment and performance.
• The size of the grant, relative to the executive's role and total compensation, appears to be within typical ranges for an EVP-level position at a company of Clorox's market capitalization, though specific peer comparisons would require detailed compensation disclosures.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term performance.

Next Steps

• Vesting of 1/4 of the Restricted Stock Units on October 5, 2026.
• Subsequent vesting installments on October 5, 2027, 2028, and 2029.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not provide new information that would materially alter the fundamental investment thesis for Clorox. While executive share acquisition is generally positive, this specific transaction is expected and does not warrant a change in investment recommendation based solely on this filing.

Keywords

Clorox, CLX, Stacey Grier, Form 4, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Equity Grant